| Description of business |
- Research and development of health check systems
- Undertaking of medical clinical laboratory tests and other examinations related to public health
- Sales and leasing of apparatus, devices and equipment for clinical laboratory tests, and of medical supplies, and installation, maintenance and repair of same
- Provision of clinical laboratory tests and clinical diagnosis services in collaboration with doctors
- Planning, development, management and operation of information systems related to medical and clinical laboratory tests, and sales and consulting services
- Analysis of risk of disease onset, summarization of test results and contract services regarding associated examinations
- Contract services regarding testing related to drugs and health foods, etc. and research, development, manufacturing, sales and import/export of such products
- Collection and distribution of samples, reagents, data and test results, etc. related to clinical laboratory tests
- Manufacture and sale of kits for DNA measurement (e.g., telomere length)
- Manufacture and sale of accessory products related to microRNA
- Introduction of pharmacists, nurses and clinical laboratory technicians to health care facilities, and corresponding mediation
- Licensing of services related to drugs, quasi-drugs, clinical laboratory reagents, and chemical agents, etc.
- Management of clinical testing laboratories
- All businesses associated with or related to any of the items listed above
|
| History |
- September 2012
- Foundation of MiRTeL Co., Ltd.
- August 2013
- Foundation of testing laboratory (address: 1-2-10 Deshio, Minami-ku, Hiroshima)
- September 2013
- Authorization as Hygiene and Public Health Center
- September 2013
- Start of contracting of Telomere test
- December 2013
- Start of contracting of MiR test® (pancreatic cancer, breast cancer, Alzheimer type dementia)
- March 2015
- Start of MiR test® cancer screening test (MiR test® Premium)
- September 2015
- Receipt of funds from NTT DOCOMO Ventures, Inc., start of joint investigation with NTT DOCOMO, INC., receipt of funds from Medical Net Communications, Inc. and business partnership
- July 2016
- Third-party share issue totaling 190 million JPY allocated to The University of Tokyo Edge Capital (UTEC) Co., Ltd., Hiroshima Venture Capital Co., Ltd., WILL GROUP, INC., NTT DOCOMO Ventures, Inc., and Medical Net Communications, Inc.
- October 2016
- Establishment of Tokyo Office (New Marunouchi Building 10F, EGG JAPAN)
- November 2016
- First prize (Prize of Chairman of the Organization for Small & Medium Enterprises and Regional Innovation) in the entrepreneur section of the ""11th awarding of the prize for creating new business in Japan"" sponsored by the Japan New Business Conference Associations.
- October 2017
- Special prize at Chugoku District tournament of the Ernst & Young ShinNihon LLC Entrepreneur of the Year 2017 Japan
- June 2018
- Third-party share issue totaling 580 million JPY allocated to Beyond Next Ventures Inc., The University of Tokyo Edge Capital (UTEC) Co., Ltd., Hiroshima Venture Capital Co., Ltd., KYOCERA Corporation and Medical Net, Inc.
- June 2018
- Start of contracting of MiR test® Platinum and telomere fatigue level test
- April 2020
- This Third-party share issue totaling 460 million JPY, is allocated to Furusato cooperation support fund investment limited partnership run by Hiroshima Innovation Network Inc., TEIJIN LIMITED, and High-Value C 1st investment limited partnership run by Hiroshima Venture Capital Co., Ltd.
- May 2020
- Acquisition of Privacy Mark.
- March 2023
- Foundation of the second laboratory (address: 1-4-8 Deshio, Minami-ku, Hiroshima)
- June 2023
- Start of Scan test
- August 2023
- Start of NAD⁺ test
- August 2023
- Authorization the second laboratory as Hygiene and Public Health Center
- January 2024
- become a subsidiary of Medical Net, Inc.
|
Hiroshima Headquarters
Tokyo Office